scholarly journals Secondary plasma cell leukaemia treated with single agent venetoclax

2020 ◽  
Vol 190 (4) ◽  
Author(s):  
Siobhan V. Glavey ◽  
Lyndsey Flanagan ◽  
Rachel Bleach ◽  
Claire Kelly ◽  
John Quinn ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Single Agent ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma

Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia

2016 ◽  
Vol 40 ◽  
pp. 30-32 ◽  
Author(s):  
Giuseppe Mele ◽  
Maria Rosaria Coppi ◽  
Gianluca Guaragna ◽  
Alessandro Spina ◽  
Angela Melpignano
Keyword(s):  
Plasma Cell ◽  
Low Dose ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma

scholarly journals Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia

2012 ◽  
Vol 157 (4) ◽  
pp. 497-498 ◽  
Author(s):  
Alessandro Gozzetti ◽  
Pellegrino Musto ◽  
Marzia Defina ◽  
Fiorella D'Auria ◽  
Giulia Papini ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma

scholarly journals Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia

2021 ◽  
Vol 195 (1) ◽  
pp. 95-107
Author(s):  
Renata Bezdekova ◽  
Tomas Jelinek ◽  
Romana Kralova ◽  
Martin Stork ◽  
Petra Polackova ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Plasma Cell ◽  
Clinical Characteristics ◽  
Plasma Cells ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma

scholarly journals Multiple gastric involvement by myeloid antigen CD13-positive non-secretory plasma cell leukaemia

1996 ◽  
Vol 92 (1) ◽  
pp. 134-136 ◽  
Author(s):  
Akimichi Ohsaka ◽  
Naotake Sato ◽  
Yasufumi Imai ◽  
Shinji Hirai ◽  
Yuji Oka ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia

Plasma cell leukaemia cutis preferentially localized to recent puncture sites

2004 ◽  
Vol 151 (1) ◽  
pp. 237-238 ◽  
Author(s):  
J.E. Kim ◽  
M-Y. Kim ◽  
H.O. Kim ◽  
Y.M. Park
Keyword(s):  
Plasma Cell ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia

Leukaemic Myelomatosis (Plasma-Cell Leukaemia)

1962 ◽  
Vol 28 (4) ◽  
pp. 222-229 ◽  
Author(s):  
Eivind B. Thorling
Keyword(s):  
Plasma Cell ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia

2 Translocations, t(11;14) and t(l;6), in a Patient with Plasma Cell Leukaemia and 2 Populations of Plasma Cells

2009 ◽  
Vol 24 (1) ◽  
pp. 42-46 ◽  
Author(s):  
Gösta Gahrton ◽  
Lore Zech ◽  
Kenneth Nillsson ◽  
Berit Lönnqvist ◽  
Anders Carlström
Keyword(s):  
Plasma Cell ◽  
Plasma Cells ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia

Primary Plasma Cell Leukaemia and Autologous Stem Cell Transplantation.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 731-731
Author(s):  
Mary B. Drake ◽  
Simona Iacobelli ◽  
Anja van Biezen ◽  
Jane F. Apperley ◽  
Dietger W. Niederwieser ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Plasma Cell ◽  
Autologous Transplantation ◽  
Cell Leukaemia ◽  
Rank Test ◽  
Tumour Mass ◽  
Data Set ◽  
Significant Difference ◽  
Plasma Cell Leukaemia

Abstract Introduction: Primary plasma cell leukaemia (PCL) is a rare disorder representing less than 5% of malignant plasma cell disease and is associated with a poor prognosis with median survivals in PCL reported at 8 to 12 months, significantly shorter than for Multiple Myeloma even when the comparison is adjusted to compare only with Multiple Myeloma of high tumour mass. Treatment of PCL with alkylating agent-based therapy is ineffective and while polychemotherapy may offer improved survival, results remain disappointing with a few exceptions. Autologous transplantation is now being used widely in the treatment of these patients and this report summarises the European Blood and Marrow Transplant (EBMT) experience of this disorder. Patients and Methods: A retrospective study was carried out with 20844 patients with common type multiple myeloma (58% IgG, 21% IgA and 19% light chain types only) and 272 patients with primary plasma cell leukaemia who underwent first autologous transplantation between 1980 and 2006. All patients were reported to the EBMT registry using MED-A (limited data set) or MED-B (more extensive data set) forms. All autografted patients were included in the study regardless of the availability of complete MED-A or MED-B data. The proportion of patients that could be evaluated for each parameter was noted and the number of evaluable patients included in the result. Comparisons between the two groups were made using Chi-squared test for categorical data and the Mann-Whitney test for continuous data. Overall Survival and Progression-Free Survival were calculated using the Kaplan-Meier method and comparisons were made using the Log-Rank test. Relapse/Progression and Death without relapse or progression probabilities were computed by the proper non-parametric estimator for outcomes with competing risks and compared by the Gray test. Results: There were no significant differences in age and gender of the PCL and myeloma groups. Calcium and albumin were also not significantly different, however, haemoglobin was significantly lower in the PCL group (11g/dl versus 9g/dl - P=0.000) while creatinine was significantly higher in the PCL group - 92 micro mol/l versus 122 micro mol/l - P=0.000). B2 microglobulin was significantly higher in the PCL group which tends to be diagnosed with a more advanced disease. There was no difference in the type of graft used or in the use of total body irradiation but the PCL group were transplanted within a shorter time from diagnosis (6.0 v 7.7 months - P=0.000). While there was no significant difference in engraftment, PCL patients were more likely than myeloma patients to enter CR post-autologous transplantation. Despite this, overall survival for the PCL patients was greatly inferior to the myeloma patients - 62.3 months (CI 60.4–64.3) versus 25.7 months (CI 19.5–31.9 - P=0.000). Poor survival is accounted for by an increase in relapse-related mortality and post-transplant responses of short duration. Conclusion: This is the largest study of plasma cell leukaemia patients ever reported. Our data shows an improved outcome for these patients with use of autologous transplantation but undoubtedly this transplant group represents the fittest of such patients and their outcome is still greatly inferior to comparable myeloma patients.

Sign in / Sign up

Export Citation Format

Share Document